BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 28, 2017
View Archived Issues
Finch Therapeutics enters collaboration with OpenBiome to develop FIN-403
Read More
S100B and CX3CR1-expressing monocytes found to be involved in brain atrophy in HIV
Read More
Funding supports DMD Therapeutics as it moves DMD-813 into drug development
Read More
GSK initiates phase I study of GSK-2292767 in healthy subjects who smoke cigarettes
Read More
Bayer initiates phase I trial of BAY-1834845
Read More
Novel murine models of NPC present main neurobehavioural and molecular features of the disease
Read More
Phase III results for utidelone plus capecitabine in heavily pretreated metastatic breast cancer
Read More
ATHOS-3 phase III study of LJPC-501 meets primary efficacy endpoint
Read More
U.S. orphan status given to eFT-508 for diffuse large B-cell lymphoma
Read More
First-in-class p300/CBP inhibitor shows potential for treating castration-resistant prostate cancer
Read More
FDA orphan drug status given to abatacept for giant cell arteritis, idiopathic inflammatory myopathy
Read More
BioCryst reports interim results from phase II Apex-1 trial of BCX-7353 in HAE
Read More
Advaxis and Sellas sign license agreement to develop cancer immunotherapy agent
Read More
FDA clears GtreeBNT to conduct phase III trial of RGN-137 in epidermolysis bullosa
Read More
Renal markers found to correlate with tenofovir-associated toxicity
Read More
Pieris grants Aska option to license PRS-080 in Japan
Read More
Cellectar updates progress of phase I trial of CLR-131 in multiple myeloma
Read More
FDA approves Qtern for type 2 diabetes
Read More
Clearside moves resources from axitinib wet AMD program to Zuprata DME development
Read More
Helix BioPharma licenses rights to anti-CEACAM6 antibody from NRC
Read More
Novo Nordisk seeks Japanese approval of once-weekly semaglutide for type 2 diabetes
Read More
Exelixis enters into clinical collaborations for cabozantinib
Read More
Arsanis signs license agreement with Adimab for rights to antibodies targeting RSV
Read More